Ara 290 vs TB-500
Extensively Studied vs Well Studied
synergistic Combined mechanisms enhance recovery from injury.
Molecular Data
Ara 290 TB-500
Weight 1,257 Da 4,963.44 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) ~2 hours
Chain 11 amino acids 43 amino acids
Type Engineered peptide Thymosin fragment
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
Ara 290 TB-500
Status Extensively Studied Well Studied
References 5 studies 4 studies
Latest — March 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.